Liverpool HIV Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Interaction

Tenofovir-DF (TDF)

Kanamycin

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied. As kanamycin is eliminated unchanged predominantly via glomerular filtration, there is little potential for interaction with tenofovir-DF via competition for active renal transport mechanisms. However, both kanamycin and tenofovir are potentially nephrotoxic and tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. If concomitant use of tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be monitored closely.

Description:

Tenofovir disoproxil fumarate has not been evaluated in patients receiving nephrotoxic medicinal products (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2). Use of tenofovir disoproxil fumarate should be avoided with concurrent or recent use of a nephrotoxic medicinal product. If concomitant use of tenofovir disoproxil fumarate and nephrotoxic agents is unavoidable, renal function should be monitored weekly.
Viread Summary of Product Characteristics, Gilead Sciences Ltd, September 2016.

Tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. Since tenofovir-DF is primarily eliminated by the kidneys, coadministration of tenofovir-DF with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of tenofovir and/or increase the concentrations of other renally eliminated drugs. Some examples include, but are not limited to, cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs.

Viread Prescribing Information, Gilead Sciences International Inc, February 2016.

View all available interactions with Tenofovir-DF (TDF) by clicking here.